Modified CMVgB protein and CMV vaccine containing the same

CN112888455BActive Publication Date: 2024-12-24KM BIOLOGICS CO
View PDF 8 Cites -1 Cited by

Patent Information

Application Number
CN201980069323.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-10-25
Filing Date
2019-10-24
Publication Date
2024-12-24
Estimated Expiration
2039-10-24

Smart Images

  • Figure GDA0003029440110000181
    Figure GDA0003029440110000181
  • Figure GDA0003029440110000211
    Figure GDA0003029440110000211
  • Figure GDA0003029440110000221
    Figure GDA0003029440110000221
Patent Text Reader

Abstract

The object of the present invention is to provide a modified CMV gB protein and a CMV vaccine comprising the same, wherein the modified CMV gB protein can induce a high-content antibody group of neutralizing antibodies showing high neutralizing activity against CMV gB protein during immune induction compared with wild-type CMV gB, and can be used to prevent and / or treat CMV infection. The modified CMV gB protein of the present invention is a modified CMV gB protein that includes a modification in the head region and has an improved ability to induce antibodies in the body region.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Genetically modified ecarin and process for producing the same

    WO2003004647A1

  • Novel antigen

    WO2012049317A2

  • Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines

    WO2015089340A1

  • Anti-transthyretin humanized antibody

    WO2015115331A1

  • Chimeric molecules and uses thereof

    CN110506060A